[Effectiveness of using immunomodulators in combined treatment of patients with chronic gastritis and ulcer disease].
Clinical and instrumental-laboratory investigations have been conducted in 372 patients with chronic antral gastritis (CAG, n = 131), diffuse gastritis (DG, n = 108) and ulcer disease (UD, n = 135). Immunomodulators tactivin and levamisol were added to standard treatment of 75 CAG, 63 DG and 85 UD patients. Healing of the lesions was observed, on the average, on the treatment day 24.3 +/- 0.5 and 18.4 +/- 0.6 in the standard treatment and with the added immunomodulator, respectively. Adjuvant levamisol diminished the number of recurrences of chronic gastritis and UD.
Arutiunian
V M
VM
Grigorian
E G
EG
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004384:Duodenoscopy; D005756:Gastritis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D013949:Thymus Extracts / Q000008:administration & dosage / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000890:Anti-Infective Agents; D009942:Organometallic Compounds; D010455:Peptides; D013949:Thymus Extracts; D007978:Levamisole; C036191:T-activin; C002791:bismuth tripotassium dicitrate